medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-13-50-53medsovet-1985Research ArticleКонтрацепцияContraceptionПРЕДМЕНСТРУАЛЬНЫЙ СИНДРОМ. НОВЫЕ ВОЗМОЖНОСТИ ТЕРАПИИPREMENSTRUAL SYNDROME NEW POSSIBILITIES OF THERAPYЛисицынаО И.LisitsynaO. I.

Москва

Moscow

ХилькевичЕ. Г.KhilkevichE. G.

д.м.н.,

Москва

MD., 

Moscow

Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава РоссииРоссияResearch Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of RussiaRussian Federation2017081020170135053Copyright © Лисицына О.И., Хилькевич Е.Г., 20172017Лисицына О.И., Хилькевич Е.Г.Lisitsyna O.I., Khilkevich E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1985

Предменструальный синдром (ПМС)  – сложный патологический симптомокомплекс, проявляющийся различными нейропсихическими, вегетативно-сосудистыми и обменно-эндокринными нарушениями, который влияет на качество жизни пациенток и снижает их работоспособность.

Лечение ПМС начинают с подбора диеты, коррекции режима труда и отдыха, максимального снижения психоэмоциональных нагрузок. С целью медикаментозного воздействия используют гормональную терапию, психотропные препараты, нестероидные противовоспалительные препараты, мочегонные, растительные и гомеопатические препараты, витаминотерапию. Наиболее патогенетически обоснованной является гормональная терапия.

Использование комбинированных оральных контрацептивов, обогащенных фолатами, в качестве терапии ПМС оказывает дополнительное эффективное воздействие на нервную систему, способствует стабилизации центральных нейрорегуляторных механизмов, а также снижению выраженности эмоционально-аффективных симптомов и когнитивных нарушений. 

The premenstrual syndrome (PMS) is a complex pathological symptom manifesting itselft through variety of neuropsychiatric, vegetative-vascular and metabolic-endocrine disorders that affect the quality of life of patients and reduces their working ability.

The treatment of PMS starts with the selection of diets, correction of the working and rest periods and the maximum reduction of psychoemotional stress. For the purpose of pharmaceutical effetc hormonal therapies, psychotropic drugs, nonsteroid antiinflammatory drugs, diuretics, plant and homeopathic drugs, vitamins are used. The most pathogenetically reasonable is hormonal therapy.

The use of combined oral contraceptives enriched by folates as a way of PMS therapy has an additional effective impact on the nervous system, contributes to the stabilization of the central neuroregulatory mechanisms and reduces the expression of  emotional and affective symptoms and cognitive disorders.

предменструальный синдромсиндром предменструального напряжениякомбинированные оральные контрацептивыдроспиренонфолиевая кислотафолатыметафолинThe premenstrual syndrome (PMS) is a complex pathological symptom manifesting itselft through variety of neuropsychiatricvegetative-vascular and metabolic-endocrine disorders that affect the quality of life of patients and reduces their working ability. The treatment of PMS starts with the selection of dietscorrection of the working and rest periods and the maximum reduction of psychoemotional stress. For the purpose of pharmaceutical effetc hormonal therapiespsychotropic drugsnonsteroid antiinflammatory drugsdiureticsplant and homeopathic drugsvitamins are used. The most pathogenetically reasonable is hormonal therapy. The use of combined oral contraceptives enriched by folates as a way of PMS therapy has an additional effective impact on the nervous systemcontributes to the stabilization of the central neuroregulatory mechanisms and reduces the expression of  emotional and affective symptoms and cognitive disorders. Keywords: premenstrual syndromeanxious premenstrual syndromecombined oral contraceptivesdrospirenonefolic acidfolatemetafolin.ReferencesUsman S, Indusekhar R, and O’Brien S. Hormonal management of premenstrual syndrome. Best Pr. Res Clin Obs. Gynaecol, 2008, 22: 251–60.Usman S, Indusekhar R, and O’Brien S. Hormonal management of premenstrual syndrome. Best Pr. Res Clin Obs. Gynaecol, 2008, 22: 251–60.Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990GÇô2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2163– 2196.Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990GÇô2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2163– 2196.Кулаков В.И., Прилепская В.Н., Радзинский В.Е. и соавт. Руководство по амбулаторно- поликлинической помощи в акушерстве и гинекологии. М.: ГЭОТАР-Медиа, 2007.Кулаков В.И., Прилепская В.Н., Радзинский В.Е. и соавт. Руководство по амбулаторно- поликлинической помощи в акушерстве и гинекологии. М.: ГЭОТАР-Медиа, 2007.Радзинский В.Е., Фукс А.М., Токтар Л.Р. и соавт. Гинекология: учебник. М.: ГЭОТАР-Медиа, 2014.Радзинский В.Е., Фукс А.М., Токтар Л.Р. и соавт. Гинекология: учебник. М.: ГЭОТАР-Медиа, 2014.Schiller CE, Johnson SL, Abate AC, Schmidt PJ, and Rubinow DR. Reproductive Steroid Regulation of Mood and Behavior. Compr. Physiol., 2016 July, 6: 1135–1160.Schiller CE, Johnson SL, Abate AC, Schmidt PJ, and Rubinow DR. Reproductive Steroid Regulation of Mood and Behavior. Compr. Physiol., 2016 July, 6: 1135–1160.Power RF, Mani SK, Codina J, Conneely OM, O’Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science, 1991, 254(5038): 1636–1639.Power RF, Mani SK, Codina J, Conneely OM, O’Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science, 1991, 254(5038): 1636–1639.Farrokh-Eslamlou H, Oshnouei S, Heshmatian B, Akbari E. Premenstrual syndrome and quality of life in Iranian medical students. Sex. Reprod. Healthc., 2015, 6(1): 23–27.Farrokh-Eslamlou H, Oshnouei S, Heshmatian B, Akbari E. Premenstrual syndrome and quality of life in Iranian medical students. Sex. Reprod. Healthc., 2015, 6(1): 23–27.Kahyaoglu Sut H, Mestogullari E. Effect of Premenstrual Syndrome on Work-Related Quality of Life in Turkish Nurses. Saf. Health Work, 2016, 7(1): 78–82.Kahyaoglu Sut H, Mestogullari E. Effect of Premenstrual Syndrome on Work-Related Quality of Life in Turkish Nurses. Saf. Health Work, 2016, 7(1): 78–82.Юренева С.В., Прилепская В.Н., Ледина А.В. Предменстуальный синдром и предместру- альное дисфорическое расстройство. Руководство по амбулаторно-поликлиниче- ской помощи в акушерстве и гинекологиию, 3-е, перераб. В.Н. Серов, Г.Т. Сухих, В.Н. Прилепская, В.Е. Радзинский. М.: ГЭОТАР- Медиа, 2016: 895–907.Юренева С.В., Прилепская В.Н., Ледина А.В. Предменстуальный синдром и предместру- альное дисфорическое расстройство. Руководство по амбулаторно-поликлиниче- ской помощи в акушерстве и гинекологиию, 3-е, перераб. В.Н. Серов, Г.Т. Сухих, В.Н. Прилепская, В.Е. Радзинский. М.: ГЭОТАР- Медиа, 2016: 895–907.Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J. Clin. Endocrinol. Metab., 2011, 96(6): 1797–1804.Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J. Clin. Endocrinol. Metab., 2011, 96(6): 1797–1804.Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing dros- pirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2012, 2: CD006586.Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing dros- pirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2012, 2: CD006586.Shehata NAA. Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: A double blind randomized placebo controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2016, 198: 100–104.Shehata NAA. Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: A double blind randomized placebo controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2016, 198: 100–104.Takeda T, Kondo A, Koga S, Hayakawa J, Hayakawa K, Hiramatsu K, Yaegashi N. Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: Open-label pilot study. J. Obstet. Gynaecol. Res., 2015, 41(10): 1584–1590.Takeda T, Kondo A, Koga S, Hayakawa J, Hayakawa K, Hiramatsu K, Yaegashi N. Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: Open-label pilot study. J. Obstet. Gynaecol. Res., 2015, 41(10): 1584–1590.Miller AL. The Methylation, Neurotransmitter, and Antioxidant Connections Between Folate and Depression. Alternative Medicine Review, 2008, 13(3): 216–226.Miller AL. The Methylation, Neurotransmitter, and Antioxidant Connections Between Folate and Depression. Alternative Medicine Review, 2008, 13(3): 216–226.Bhatia P, Singh N. Homocysteine excess: Delineating the possible mechanism of neurotoxicity and depression. Fundam. Clin. Pharmacol., 2015, 29(6): 522–528.Bhatia P, Singh N. Homocysteine excess: Delineating the possible mechanism of neurotoxicity and depression. Fundam. Clin. Pharmacol., 2015, 29(6): 522–528.Anderson DN, Abou-Saleh MT, Collins J. Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT. Psychol Med, 1992, 22: 863– 869.Anderson DN, Abou-Saleh MT, Collins J. Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT. Psychol Med, 1992, 22: 863– 869.Ghadirian AM, Ananth J, Engelsmann F. Folic acid deficiency and depression. Psychosomatics, 1980, 21: 926–929.Ghadirian AM, Ananth J, Engelsmann F. Folic acid deficiency and depression. Psychosomatics, 1980, 21: 926–929.Reynolds EH, Preece JM, Bailey J, Coppen A. Folate deficiency in depressive illness. Br J Psychiatry, 1970, 117: 287–292.Reynolds EH, Preece JM, Bailey J, Coppen A. Folate deficiency in depressive illness. Br J Psychiatry, 1970, 117: 287–292.Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J. Epidemiol. Community Heal., 2007, 61(7): 631–637.Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J. Epidemiol. Community Heal., 2007, 61(7): 631–637.Watanabe H, Ishida S, Konno Y, Matsumoto M, Nomachi S, Masaki K, Okayama H, Nagai Y. Impact of Dietary Folate Intake on Depressive Symptoms in Young Women of Reproductive Age. J. Midwifery Womens. Health, 2012, 57(1): 43–48.Watanabe H, Ishida S, Konno Y, Matsumoto M, Nomachi S, Masaki K, Okayama H, Nagai Y. Impact of Dietary Folate Intake on Depressive Symptoms in Young Women of Reproductive Age. J. Midwifery Womens. Health, 2012, 57(1): 43–48.Askari G, Nasiri M, Mozaffari-khosravi H, Rezaie M, Bidakhavidi MB, Sadeghi O. The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blinded randomized placebo-controlled clinical trial. Nutrition, 2017, 38: 74–79.Askari G, Nasiri M, Mozaffari-khosravi H, Rezaie M, Bidakhavidi MB, Sadeghi O. The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blinded randomized placebo-controlled clinical trial. Nutrition, 2017, 38: 74–79.Troen AM. Folate and vitamin B12: function and importance in cognitive development. Nestl?? Nutr. Inst. Work. Ser., 2012, 70: 161–171.Troen AM. Folate and vitamin B12: function and importance in cognitive development. Nestl?? Nutr. Inst. Work. Ser., 2012, 70: 161–171.Authors A, Plumptre L, Masih SP, Ly A, Aufreiter S, Sohn K, Croxford R, Andrea Y. High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood. Am. J. Clin. Nutr., 2015: 848–857.Authors A, Plumptre L, Masih SP, Ly A, Aufreiter S, Sohn K, Croxford R, Andrea Y. High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood. Am. J. Clin. Nutr., 2015: 848–857.Lu X, Wu J, Bao Y. Polymorphisms in MTHFD1 Gene and Susceptibility to Neural Tube Defects : A Case- Control Study in a Chinese Han Population with Relatively Low Folate Levels. Med. Sci. Monit., 201., 21: 2630–2637.Lu X, Wu J, Bao Y. Polymorphisms in MTHFD1 Gene and Susceptibility to Neural Tube Defects : A Case- Control Study in a Chinese Han Population with Relatively Low Folate Levels. Med. Sci. Monit., 201., 21: 2630–2637.Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, Vitamin B12, Homocysteine, and the MTHFR 677C→T Polymorphism in Anxiety and Depression. Arch. Gen. Psychiatry, 2003, 60(6): 618.Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, Vitamin B12, Homocysteine, and the MTHFR 677C→T Polymorphism in Anxiety and Depression. Arch. Gen. Psychiatry, 2003, 60(6): 618.Philip D, Buch A, Moorthy D, Scott TM, Parnell LD, Lai CQ, Ordovás JM, Selhub J, Rosenberg IH, Tucker KL, Troen AM. Dihydrofolate reductase 19-bp deletion polymorphism modifies the association of folate status with memory in a cross-sectional multiethnic study of adults. Am. J. Clin. Nutr., 2015, 102(5): 1279–1288.Philip D, Buch A, Moorthy D, Scott TM, Parnell LD, Lai CQ, Ordovás JM, Selhub J, Rosenberg IH, Tucker KL, Troen AM. Dihydrofolate reductase 19-bp deletion polymorphism modifies the association of folate status with memory in a cross-sectional multiethnic study of adults. Am. J. Clin. Nutr., 2015, 102(5): 1279–1288.Eszlari N, Kovacs D, Petschner P, Pap D, Gonda X, Elliott R, Anderson IM, Deakin JFW, Bagdy G, Juhasz G. Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression. Transl. Psychiatry, 2016, 6(3): e745.Eszlari N, Kovacs D, Petschner P, Pap D, Gonda X, Elliott R, Anderson IM, Deakin JFW, Bagdy G, Juhasz G. Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression. Transl. Psychiatry, 2016, 6(3): e745.

The authors declare that there are no conflicts of interest present.